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Abstract
Background: While beneficial health effects of fish and fish oil consumption are well documented, the incorporation of n-3
polyunsaturated fatty acids in plasma lipid classes is not completely understood. The aim of this study was to investigate
the effect of fish oil supplementation on the plasma lipidomic profile in healthy subjects.
Methodology/Principal Findings: In a double-blinded randomized controlled parallel-group study, healthy subjects
received capsules containing either 8 g/d of fish oil (FO) (1.6 g/d EPA+DHA) (n = 16) or 8 g/d of high oleic sunflower oil
(HOSO) (n = 17) for seven weeks. During the first three weeks of intervention, the subjects completed a fully controlled diet
period. BMI and total serum triglycerides, total-, LDL- and HDL-cholesterol were unchanged during the intervention period.
Lipidomic analyses were performed using Ultra Performance Liquid Chromatography (UPLC) coupled to electrospray
ionization quadrupole time-of-flight mass spectrometry (QTOFMS), where 568 lipids were detected and 260 identified. Both
t-tests and Multi-Block Partial Least Square Regression (MBPLSR) analysis were performed for analysing differences between
the intervention groups. The intervention groups were well separated by the lipidomic data after three weeks of
intervention. Several lipid classes such as phosphatidylcholine, phosphatidylethanolamine, lysophosphatidylcholine,
sphingomyelin, phosphatidylserine, phosphatidylglycerol, and triglycerides contributed strongly to this separation. Twenty-
three lipids were significantly decreased (FDR,0.05) in the FO group after three weeks compared with the HOSO group,
whereas fifty-one were increased including selected phospholipids and triglycerides of long-chain polyunsaturated fatty
acids. After seven weeks of intervention the two intervention groups showed similar grouping.
Conclusions/Significance: In healthy subjects, fish oil supplementation alters lipid metabolism and increases the proportion
of phospholipids and triglycerides containing long-chain polyunsaturated fatty acids. Whether the beneficial effects of fish
oil supplementation may be explained by a remodeling of the plasma lipids into phospholipids and triglycerides of long-
chain polyunsaturated fatty acids needs to be further investigated.
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Introduction
Intake of fish and fish oil, containing n-3 fatty acids;
eicosapentaenoic acid (EPA; 20:5) and docosahexaenoic acid
(DHA; 22:6), is associated with beneficial health effects such as
reduced risk of cardiovascular disease and sudden cardiac death
[1–4]. The beneficial effects of marine n-3 fatty acids have been
explained by decreased plasma triglycerides (TGs) [5,6], moderate
reduction in blood pressure [7], reduced platelet aggregation [8,9],
and protection against cardiac arrhythmias [10,11]. It has been
suggested that bioactive lipid components may be important in
mediating these effects, but the molecular mechanisms are still to a
large extent unknown.
PLOS ONE | www.plosone.org 1 August 2012 | Volume 7 | Issue 8 | e42550
Cells, tissues and biological fluids contain tens of thousands of
structurally different lipids, that fulfil multiple roles in cellular
signalling, in membrane structure, and as fuel sources for many
cell types [12]. The entire spectrum of lipids in a biological system,
can be defined as the lipidome [13], which combines mass
spectrometry technology and bioinformatics methods with tradi-
tional methods such as sample preparation, lipid extraction and
separation. Lipidome analyses have revealed a diversity of lipid
compounds in human plasma, which can be classified into six
main lipid categories including fatty acyls, glycerolipids, glycer-
ophospholipids, sphingolipids, sterol lipids and prenol lipids [14].
The major plasma lipids are the glycerolipids (TGs), glyceropho-
spholipids (phospholipids) and sterol lipids which are transported
in the lipoprotein particles [14,15].
In n-3 FA intervention studies fatty acids have been measured in
different blood compartments such as in platelets and red blood
cells, and in plasma cholesteryl esters, triglycerides and phospho-
lipids. Lipidomic analysis now offers the opportunity to detect
exact fatty acid composition of these individual lipids. [16].
Recently it was shown that the plasma lipidomic profile was
altered in subjects with coronary heart disease after intake of fatty
fish, and in subjects with metabolic syndrome after consumption of
a healthy diet containing fatty fish, wholegrain products and
bilberries [17,18]. Furthermore, profiling of the plasma lipids
suggests a relationship between the composition of plasma lipids
and diet [19,20], with diet-induced weight loss [21] and diet-
related diseases such as diabetes mellitus [22]. This opens up the
opportunity to identify new functional lipid biomarkers to detect
and prevent diet-related diseases. We have however not been able
to find studies showing the plasma lipidomic profile in healthy
subjects after intake of fish oil.
We have previously reported that in the present study a daily
intake of fish oil (1.6 g EPA+DHA/d) did not change the level of
serum lipids, markers of oxidative stress, lipid oxidation or
inflammation, whereas an increase in plasma EPA, DPA and
DHA was observed after three and seven weeks of intervention in
a randomized controlled study in healthy subjects [23]. The aim of
this study was to apply a lipidomic strategy to further describe the
effect of fish oil supplementation in healthy subjects.
Materials and Methods
Subjects
Healthy men and women between 18–50 years were recruited
into this study. Detailed description of the protocol, participant
recruitment and enrolment, inclusion and exclusion criteria, and
compliance are described in details elsewhere [23]. In brief,
exclusion criteria were total cholesterol .7.5 mmol/l, triglycerides
.4 mmol/l, glucose .6.0 mmol/l, C-reactive protein (CRP)
.10 mg/l, body mass index (BMI) $30 kg/m2 and blood
pressure ($160/100). The study was performed at the Akershus
University College, Norway between September and December
2009.
Ethics Statement
Written informed consent was obtained from all participants
and the protocol was approved by the Regional Committee of
Medical Ethics (approval no. 6.2008.2215) and by the Norwegian
Social Science Data Services (approval no. 21924), and was
conducted in accordance with the Declaration of Helsinki.
Study Design
This study was a part of a randomized controlled double-
blinded three-arm parallel group study, designed to investigate
health effects from intake of fish oil [23]. In the present study, data
from two of the intervention groups are included, as shown in
Figure 1. Subjects in the present study were given 8 g/d of either
fish oil (FO) or high oleic sunflower oil (HOSO), and each subject
was taking 16 capsules/d minimum twice each day for seven
weeks. Subjects in the fish oil group received capsules containing
0.7 g/d EPA+0.9 g/d DHA from cod liver oil (Gadidae sp., TINE
EPADHA Oil 1200) provided by TINE SA (Oslo, Norway) and
subjects in the control group received high oleic sunflower oil
purchased from AarhusKarlshamn AB (Malmø, Sweden). The
subjects were instructed to take the capsules with food (minimum
two meals). The fatty acid composition in the oils has been
described elsewhere [23].
The subjects met for visits and blood samples for the lipidome
analyses were collected at 0, 3 and 7 weeks. Between the screening
and baseline visit (week 0), the subjects conducted a four-week
washout period, where foods containing marine n-3 fatty acids
were avoided. During the first three weeks of the intervention the
subjects conducted a fully-controlled isocaloric diet, provided with
all food and beverages at Akershus University College, Norway.
The mean daily intake during the fully controlled diet period
(exclusive capsules, n = 33) was 9.162.3 MJ and the composition
of the diet consumed was similar in both groups containing
24.461.1 percentage of energy (E%) from fat, of which 7.860.3
E% from SFA, 5.860.4 E% from MUFA and 4.860.9% PUFA.
The carbohydrate content was 54.461.1 E%, including 4.660.9
E% from added sugar and 19.460.5 E% from protein. The food
items provided in this study have previously been described [23].
The last four weeks of the intervention period the subjects
returned to their habitual diet. Intake of fish, fish products, marine
n-3 enriched food or dietary supplements was not allowed during
the entire study period of 11 weeks. The study was registered at
www.clinicaltrial.gov (IDno. NCT01034423).
Blood sampling
Subjects were told to refrain from alcohol consumption and
vigorous physical activity the day prior to blood sampling. Venous
blood samples were drawn after an overnight fast ($12 hours) at
the same time (62 h) and serum were kept at room temperature at
30 min before centrifuged (1500 g 12 min). EDTA-plasma was
immediately placed on ice and centrifuged within 10 min (1500 g,
4uC, 10 min). N2 flushed plasma samples were snap frozen and
stored at 280uC until further analysis.
Routine laboratory analysis
Fasting serum hsCRP, total- cholesterol, LDL-cholesterol,
HDL-cholesterol, triglycerides and glucose were measured by
standard methods at a routine laboratory (Fu¨rst Medical
Laboratory, Oslo, Norway).
Lipidomic analyses
An aliquot (10 mL) of plasma sample was diluted with 10 mL of
0.15 M (0.9%) sodium chloride and 10 mL of internal standard
mixture containing PC(17:0/0:0), PC(17:0/17:0), PE(17:0/17:0),
PG(17:0/17:0)[rac], Cer(d18:1/17:0), PS(17:0/17:0) and PA(17:0/
17:0) (Avanti Polar Lipids, Inc., Alabaster, AL, USA) and
TG(17:0/17:0/17:0) and MG(17:0/0:0/0:0)[rac], DG(17:0/
17:0/0:0)[rac] (Larodan Fine Chemicals) was added. The lipids
were extracted using a mixture of HPLC-grade chloroform and
methanol (2:1; 100 mL). The lower phase was collected (60 mL)
and 10 mL internal standard mixture containing labeled PC(16:1/
0:0-D3), PC(16:1/16:1-D6) and TG(16:0/16:0/16:0-
13C3) was
added.
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The extracts were analyzed on a Waters Q-Tof Premier mass
spectrometer combined with an Acquity Ultra Performance LCTM
(UPLC) in randomized order. The column (at 50uC) was an
Acquity UPLCTM BEH C18 2.16100 mm with 1.7 mm particles.
The solvent system included A: ultrapure water with 1% 1 M
NH4Ac and 0.1% HCOOH, and B: LC/MS grade acetonitrile/
isopropanol (1:1) with 1% 1M NH4Ac and 0.1% HCOOH. The
gradient started from 65% A/35% B, reached 80% B in 2 min,
100% B in 7 min and remained there for 7 min. The flow rate was
0.400 ml/min and the injected amount was 2.0 ml (Acquity
Sample Organizer, at 10uC). Reserpine was used as the lock
spray reference compound. The lipid profiling was carried out
using ESI+ mode and the data was collected at mass range of m/z
300–1200 with scan duration of 0.2 sec. The data was processed
by using MZmine2 software [24] and the lipid identification was
based on an internal spectral library.
The data processing included peak detection, integration, peak
alignment, normalization and identification. Lipids were identified
Figure 1. Flow chart of the study showing subjects enrolled, lost during follow-up and number of subjects included in the statistical
analysis at baseline and after three and seven weeks of fish oil supplementation. FO group, fish oil group; HOSO, high oleic sunflower oil
group; oxFO, oxidized fish oil group (not included in the present study).
doi:10.1371/journal.pone.0042550.g001
Table 1. BMI and serum lipids at baseline and after three weeks of intervention with fish oil (n = 16) and high oleic sunflower oil
(n = 17).
Fish oil Sunflower oil
Parameter Baseline 3 wk Baseline 3 wk P-value* P-value**
BMI (kg/m2) 2263 2263 2363 2363 0.25 0.53
Triglycerides (mmol/l) 0.960.4 0.960.3 1.160.7 1.160.4 0.46 0.68
Total-cholesterol (mmol/l) 4.660.8 4.460.6 4.960.9 4.661.0 0.27 0.36
LDL-cholesterol (mmol/l) 2.560.8 2.460.8 2.760.6 2.660.6 0.35 0.64
HDL-cholesterol (mmol/l) 1.560.3 1.460.4 1.560.4 1.460.4 1 0.86
*Independent t- test for between groups at baseline.
**Independent t- test for changes between groups after three weeks.
doi:10.1371/journal.pone.0042550.t001
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using an internal spectral library. The data was normalized using
internal standards representative of each class of lipid present in
the samples: the intensity of each identified lipid was normalized
by dividing it with the intensity of its corresponding standard and
multiplying it by the concentration of the standard. All monoacyl
lipids except cholesterol esters, such as monoacylglycerols and
monoacylglycerophospholipids, are normalized with PC(17:0/0:0),
all diacyl lipids except ethanolamine phospholipids are normalized
with PC(17:0/17:0), all ceramides with Cer(d18:1/17:0), all diacyl
ethanolamine phospholipids with PE(17:0/17:0), and TG and
cholesterol esters with TG(17:0/17:0/17:0).
Statistical analyses
Sample size was calculated using expected change in plasma n-3
fatty acids as described as previously described [23]. Multi-Block
Partial Least Squares Regression (MBPLSR) analysis was used for
exploring the sample and variable variation patterns in the data
[25] where each lipid class was defined as one individual block
[26] resulting in 11 blocks of descriptor variables in total (i.e.
½X1,X2,:::,X11). The multi-block set of descriptor variables were
organized in the following order: Ceramides as block one (X1),
lysophosphatidylcholines (lysoPC) as block two (X2), lysopho-
sphatidylethanolamines (lysoPE) as block three (X3), phosphatidic
acid (PA) as block four (X4), phosphatidylcholines (PC) as block
five (X5), phosphatidylethanolamines (PE) as block six (X6),
phosphatidylglycerols (PG) as block seven (X7), phosphatidylser-
ines (PS) as block eight (X8), sphingomyelins (SM) as block nine
(X9), triglycerides (TG) as block ten (X10) and sums of lipid classes
together with phosphatidylinositol (PI) as block eleven (X11) (a
separate block was not assigned to PI class since it contained only
one lipid). An intervention group indicator variable was used as
response variable (y-variable). In order to estimate both the
influence of the total amount of lipids in each lipid class and
simultaneously the influence of the relative variation within each
lipid class, each block was normalized by a division by the total
amount of lipids in the corresponding class. The total amounts of
lipids of each lipid classes were then used as an additional block
and named ‘‘the sums of lipids’’. Subsequently, plasma lipids were
transformed by taking the log2 ratio (baseline adjusted log2 values)
after three and seven weeks in both the FO and the HOSO group.
After this, each block (lipid class) was set on the same footing prior
to MBPLSR analysis by block scaling as described in [26]. Model-
validation and testing of the influence of each lipid class to the
global model was done by cross-validation as described in
Figure 2. Multi-Block Partial Least Squares Regression (MBPLSR) analysis of the data after three weeks of intervention. First and
second PLSR components of block scores of ceramides, lysoPC, lysoPE, PA, PC and PE are shown (A–F). The samples of each intervention group are
presented as blue (HOSO group) or red (FO group) circles. The (un-validated) explained variances are shown on the axes.
doi:10.1371/journal.pone.0042550.g002
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[26].Variable significance testing for the difference between the
groups at baseline and after the intervention (baseline adjusted
values) was done by cross-validation [25,26] of the multivariate
MBPLSR model and by univariate testing using Student’s- t test.
For the univariate testing the log2 ratios were used and False
Discovery Rate (FDR) corrected q-values were computed using the
R package ‘qvalue’. Two subjects were detected as outliers by the
MBPLSR models and were therefore excluded from the further
analysis. Baseline characteristics were analyzed using (baseline
adjusted values) Student’s- t test and Mann Whitney U test (serum
triglycerides) when data was normally and not normally distrib-
uted, respectively. The significance level was set to 5% (two-sided)
and the power of the test was chosen to be 80%. Data in Table 1
are presented as mean 6 SD. All univariate analyses were
performed using SPSS for windows (SPSS, version 19.0) and
multivariate analyses were performed using in-house-written and
standard MATLAB routines (MATLAB version 7.8).
Results
Characteristics of the subjects
A total of 33 normal weight healthy subjects (n = 8 men and
n=25 women) completed this study. The subjects were young
(2868 years), and with serum lipids within the normal range as
shown in Table 1. No differences in age, BMI or serum lipids were
observed between the FO group (n= 16) and the HOSO group
(n= 17) at baseline (Table 1). Serum lipids and BMI were not
significantly changed between the groups after three (Table 1) or
seven weeks of intervention (data not shown).
Plasma lipidomic profile
A total of 568 lipids were detected and quantified in the plasma
samples of the two intervention groups. Of these lipids, 260 were
identified, including the following lipid classes; ceramides,
sphingomyelins (SM), lysophosphatidylcholines (lysoPC), lysopho-
sphatidylethanolamines (lysoPE), phosphatidic acids (PA), phos-
phatidylcholines (PC), phosphatidyethanolamines (PE), phospha-
tidylglycerols (PG), phosphatidylinositols (PI), phosphatidyserines
(PS) and triglycerides (TG). In the present study, the identified
lipids were included in the statistical analysis.
MBPLSR was performed with lipid class blocks as a multi-block
X and intervention group indicator variable as y-variable. The
lipid class block variation patterns after three weeks of intervention
are shown in Figure 2 and Figure 3A–D. The lipidomic profiles of
the two intervention groups were well separated in the global
sample variation pattern (global score plot) (Figure 3F). The first
principal component accounted for most of the separation of the
two groups and explained 91.5% of the total variance in the y-
Figure 3. Multi-Block Partial Least Squares Regression (MBPLSR) analysis of the data after three weeks of intervention. First and
second PLSR components of block scores of PG, PS, SM, TG, the sums of lipid classes and global scores are shown (A–F). The samples of each
intervention group are presented as blue (HOSO group) or red (FO group) circles. The (un-validated) explained variances are shown on the axes.
doi:10.1371/journal.pone.0042550.g003
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variable. The explained block variances are shown on the
respective axes. Several lipid class blocks (lysoPC, PC, PE, PG,
PS, SM and TG) showed a clear separation of the FO and the
HOSO group, whereas ceramides, lysoPE and PA lipids did not
separate the FO and the HOSO group (Figure 2 and Figure 3A–
D). In addition, the sums of lipid classes did not separate the FO
and the HOSO group (Figure 3E) showing that the differences
between FO and HOSO group can be explained by remodelling
within lipid classes rather than by changes in the total amount of
lipids in each class. A similar separation of the groups and patterns
in block score plots were observed also after seven weeks of
intervention (data not shown). To further analyze the plasma lipid
profile and to identify specific lipids contributing to the separation,
we decided to use the data obtained after completing a three weeks
fully controlled diet period. After three weeks of intervention, the
contribution of each lipid class block to the prediction of the group
indicator variable was validated by calculating root mean squared
errors of cross-validation per block. The validated explained
variances for the first two components are shown in Figure 4. The
first principal component of the lysoPC, PC, PE and SM lipid
classes described most of the group separation and explained more
than 70% of the y-variance. The second component of the PG, PS
and TG lipids explained the separation of the two intervention
groups further accounting for 19–37% of the y-variance. By
significance testing using cross-validation and Jack-knifing [26] a
total of 75 lipids were identified as significant for the separation of
the two intervention groups after three weeks using a two principal
component model (Table S1). By investigating the validated root
mean squared error as a function of components a two component
model was selected (Figure S1).
To further identify the specific lipids that contributed to the
distinction of the FO and the HOSO group correlation loading
plots were studied [26]. The correlation loading plots in Figures 5
and 6 show that several phospholipids and TGs containing long-
chain PUFAs including lysoPC(20:5), lysoPC(22:6), PC(36:5),
PC(40:6), PE(38:5), TG(50:4), TG(52:6), TG(52:7), TG(54:8),
TG(56:7), TG(56:8), TG(56:9), TG(58:6), TG(58:8), TG(58:9),
and TG(58:10) were strongly positively correlated to intake of FO
supplementation.
A strong positive correlation was also observed between intake
of FO supplementation and lipids of long-chain and lower double
bond content such as SM(18:0/24:0), TG(59:2) and TG(52:0).
Only PC(40:4e), PC(37:4)/PE(40:4), PC(38:5) and PC(34:2) were
found negatively correlated to the FO group.
In order to describe altered lipids in the FO group compared to
the HOSO group unpaired t-test was performed. In the FO group,
74 lipids were significantly altered (FDR,0.05) compared with the
HOSO group after three weeks of intervention, and 51 out of
Figure 4. Cross-validated explained variance in Y. Bar plots of the validated explained variances in Y for each block and for the global model
using data obtained after three weeks of intervention are presented.
doi:10.1371/journal.pone.0042550.g004
Fish Oil and Lipidomics
PLOS ONE | www.plosone.org 6 August 2012 | Volume 7 | Issue 8 | e42550
these 74 lipids were significantly increased. Several phospholipids
and TGs containing long-chain PUFAs were increased in the FO
group, compared to the HOSO group. Significantly altered
lysoPC, PC, PE, PA, PG, PS, PI, SM and TG lipids are shown in
Tables 2 and 3. Furthermore, 49 lipids were identified as
significantly altered in the FO group compared to the HOSO
group by both unpaired t-test and MBPLSR (Table S1). After
seven weeks of intervention 58 significant altered lipids were
identified in the FO group compared to the HOSO group, and 33
out of these 58 lipids were significantly altered after both three and
seven weeks (data not shown).
Discussion
We have investigated the effect of fish oil supplementation on
the plasma lipidomic profile in healthy subjects. A clear distinction
of the lipidomic profile was obtained between the FO and the
HOSO group after three and seven weeks of intervention. The
lipid classes that contributed to the separation of the intervention
groups were LysoPC, PC, PE, PG, PS, SM and TG. FO
supplementation especially increased phospholipids and TGs of
long-chain PUFAs, but the total concentration of the lipids within
each lipid class remained unchanged and did not differ in the FO
compared to the HOSO group. The clear distinction between the
FO and the HOSO group was observed after a fully-controlled
isocaloric diet period for three weeks and it was also evident after
the subjects had continued on their habitual diet for additionally
four weeks. HOSO was used as control oil due to a similar lipid
composition as the background diet, and the expected change in
plasma lipidome after intake of HOSO were thought to be small.
Figure 5. Multi-Block Partial Least Squares Regression (MBPLSR) analysis of the data after three weeks of intervention. Correlation
loading plot for the variables contributing to the separation of the FO and the HOSO group after three weeks are shown for LycoPC, PE, PG, PS and
SM. The (un-validated) explained variances in X and Y are shown on the axes.
doi:10.1371/journal.pone.0042550.g005
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By using MBPLSR, co-variation patterns in sample and variable
space for the different lipid classes was studied. MBPLSR is a
method based on latent variables, where by using only few latent
variables the problem of over-fitting and false discovery is
minimized. For MBPLSR analysis data blocks were organized
and normalized, such that remodelling effects in each lipid class
and changes in total amounts of lipids per class could be studied
separately. A possible consequence of organizing the data into
lipid classes is that patterns in the dataset related to other features
maybe overlooked. We also included univariate analyses were the
data was not organized into lipid classes. The univariate analyses
will produce many false significant lipids due to the high number
of variables and therefore false discovery adjusted q-values were
computed. The majority of the significant altered lipids identified
with univariate analyses were also identified as changed with
multivariate analyses, indicating that the organization into lipid
classes did not influenced the identification of significant altered
lipids.
Recent results from a dietary intervention study have shown
that fish intake increased TGs of long-chain PUFA similar to our
results, and that fish consumption for eight weeks increased plasma
long-chain TGs in subjects with coronary heart disease [18].
Interestingly, this effect was significant after intake of lean fish and
not fatty fish [18]. A healthy diet rich in whole grain products, fish
and bilberries significantly changed multiple TGs incorporating
long-chain PUFAs after 12 weeks intervention in subjects with
Figure 6. Multi-Block Partial Least Squares Regression (MBPLSR) analysis of the data after three weeks of intervention. Correlation
loading plot for the variables contributing to the separation of the FO and the HOSO group after three weeks are shown for TG and PC. The (un-
validated) explained variances in X and Y are shown on the axes.
doi:10.1371/journal.pone.0042550.g006
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impaired glucose metabolism [17]. Fish oil supplementation was
previously found to reduce the total plasma TG concentration by
selectively reducing short chain fatty acids and to increase various
phospholipids [27]. Thus, it is reasonable to assume that intake of
fish and fish oil causes a remodeling of plasma TG species towards
more long-chained fatty acids. Our results demonstrate that this
remodeling occurs in healthy subjects where the total serum TG
level and the BMI are unchanged.
We observed an increase in several phospholipids incorporating
n-3 PUFAs, such as lysoPC(20:5) and lysoPC(22:6) in the FO
group compared to the HOSO group. An association between n-3
FA intake and changes in lysoPC has previously been described
[18,28], and in accordance with our results, lysoPC(20:5) was
significantly increased in subjects with impaired glucose metabo-
lism after a healthy diet containing fatty fish [17]. In contrast, fatty
fish consumption for eight weeks in subjects with CVD decreased
the total concentration of lysoPC [18]. In addition, Block and
colleagues found that FO supplementation increased the EPA and
Table 2. Significantly altered lipids (FDR,0.05) in the fish oil
(FO) group compared to the sunflower oil group (HOSO) after
three weeks of intervention.
Fold change from baseline
Lipid Name q-value HOSO FO
LysoPC(20:5) ,0.001 0.80 4.35
LysoPC(22:5) 0.025 0.91 1.67
LysoPC(22:6) 0.003 0.94 1.89
PA(38:5e) 0.006 1.05 0.75
PE(38:4) 0.026 1.11 0.88
PE(38:4)+PC(35:4) 0.029 1.27 0.90
PE(38:5) ,0.001 0.92 3.29
PE(38:5e) 0.042 1.09 0.75
PE(38:7e) ,0.001 1.17 2.58
PE(38:7e) 0.013 1.11 1.40
PE(40:4) 0.027 1.10 0.78
PE(40:6) 0.013 1.10 1.75
PE(40:7e) 0.010 1.08 1.51
PG(36:2) 0.015 0.96 0.68
PG(36:5e) 0.028 1.02 0.80
PG(38:4) 0.013 1.24 0.89
PG(40:6) 0.003 1.11 1.91
PI(40:7) 0.024 1.25 0.96
PS(36:1) 0.001 1.14 1.84
PS(38:0) 0.031 1.18 1.67
PS(38:1) 0.010 1.11 1.58
PS(38:1) 0.019 1.26 1.83
PS(41:5) 0.031 1.17 0.96
PS(42:1) 0.003 1.09 1.86
PS(42:6) 0.001 0.96 1.54
PS(42:7) 0.001 0.92 1.39
PS(42:8) 0.001 1.36 2.51
PS(44:1) 0.001 1.08 1.86
SM(d18:0/20:0) 0.029 1.08 0.81
SM(d18:0/22:6) 0.015 1.01 1.44
SM(d18:0/24:0) ,0.001 0.93 2.62
SM(d18:1/26:2) 0.015 1.10 1.43
doi:10.1371/journal.pone.0042550.t002
Table 3. Significantly altered lipids (FDR,0.05) in the fish oil
(FO) group compared to the sunflower oil (HOSO) group after
three weeks of intervention.
Fold change from baseline
Lipid Name q-value HOSO FO
PC(30:3) 0.015 0.85 0.6
PC(32:5) 0.024 1.03 0.77
PC(36:3) 0.031 0.97 0.73
PC(36:5) ,0.001 0.80 4.00
PC(37:4)/PE(40:4) 0.021 1.07 0.83
PC(38:1) 0.025 1.05 1.60
PC(38:1e) 0.026 0.91 1.39
PC(38:4) 0.007 2.35 9.08
PC(38:5) ,0.001 1.12 3.97
PC(38:5e) 0.006 1.2 0.96
PC(38:6) 0.006 1.15 1.52
PC(38:6) 0.037 0.89 0.69
PC(38:7) 0.001 1.09 2.27
PC(38:7) 0.001 1.09 2.25
PC(40:2) ,0.001 0.99 3.54
PC(40:3) 0.001 0.93 1.74
PC(40:4) 0.029 1.09 0.79
PC(40:4e) 0.015 1.01 0.78
PC(40:5) ,0.001 0.89 1.57
PC(40:6) ,0.001 1.04 1.71
TG(50:4) ,0.001 1.04 3.57
TG(52:0) 0.001 1.03 2.52
TG(52:2) 0.029 1.09 0.79
TG(52:6) 0.004 0.96 2.86
TG(52:7) ,0.001 0.80 4.55
TG(54:2) 0.001 1.27 0.59
TG(54:3) 0.029 1.26 0.83
TG(54:4) ,0.001 0.96 2.34
TG(54:4) 0.003 0.97 1.73
TG(54:5) 0.022 1.51 0.82
TG(54:8) ,0.001 0.98 5.02
TG(56:2) 0.026 1.02 1.93
TG(56:4) 0.038 4.50 1.47
TG(56:7) ,0.001 1.09 3.02
TG(56:8) ,0.001 1.27 2.71
TG(56:9) ,0.001 1.01 4.76
TG(58:10) ,0.001 1.17 4.14
TG(58:6) 0.003 1.17 2.10
TG(58:6) 0.023 0.99 1.70
TG(58:8) ,0.001 1.36 4.07
TG(58:9) 0.001 1.48 4.05
TG(59:2) ,0.001 1.08 2.73
doi:10.1371/journal.pone.0042550.t003
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DHA species of lysoPC in healthy individuals [28]. The potential
health effect of altering the blood plasma concentration of EPA
and DHA lysoPC compounds is uncertain. However, the
biological functions of lysoPC compounds are assumed to vary
with the degree of saturation and acyl length [28] and LysoPC has
been suggested as the major carrier of DHA to brain tissues [29].
Three out of four significantly altered SM lipids were increased
in the FO group compared to the HOSO group. SM lipids are the
most dominant circulating sphingolipid representing 88% of the
total concentration in blood, whereasceramides account for
approximately 3% [30]. SM in blood is key components and
exists predominantly in the hydrophobic outer layer of lipoprotein
particles. Of the lipoprotein particles, the VLDL particle contains
the highest amount of SM lipids [31]. However, the localization,
distribution and role SM lipid species among the lipoprotein
particles is still obscure.
In the present study, FO supplementation was not associated
with changes in plasma PA, lysoPE and ceramides, indicating that
n-3 PUFA is selectively incorporated into other lipid classes.
Ceramides have been associated with inflammation and cardio-
vascular disease [32,33]. However, high content of specific C24
ceramides have been linked to less atherogenic lipoprotein
particles in healthy subjects [31]. Lankinen et al. observed that
the total concentration of ceramides decreased after fatty fish
consumption for eight weeks [18]. The discrepancies observed
between these studies may be due to differences in the study
population and design, or due to lack of specific bioactive
components in fish oil which are normally present in fish.
Lipid profiling has identified a relation between lipid acyl chain
structure and risk of disease [22]. The present study shows that fish
oil supplement increases the level of lipids such as TG(56:9),
TG(58:10), LysoPC(22:6) and PC(38:6). These lipid species were
recently associated with decreased risk of diabetes, when lipidome
analyses were applied to plasma obtained from participants in the
Framingham heart cohort study [22]. In that study a higher
carbon number and higher double bond content were associated
with decreased risk of diabetes. Thus, long-chain highly unsatu-
rated TGs that have been associated with diabetes risk reduction
were increased after intake of fish oil in the present study.
Whether the beneficial effects of fish oil supplementation may
be explained by a remodeling of the plasma lipids into TGs and
PLs of long-chain PUFAs, needs to be further investigated.
However, PUFAs incorporated into TGs and PLs may reach
tissues, cells and lipoproteins by a selective lipid exchange [34]. In
the tissues, EPA and DHA can be incorporated into membranes
and cause alterations in signaling pathways and the formation of
lipid mediators that are important in inflammation [35,36]. In
addition, EPA and DHA or their oxidation products have the
ability to activate transcription factors both in the liver and in
other metabolic active tissues and increase the expression of target
genes involved in lipid metabolism and inflammation [37–40].
Altering the lipid composition of lipoprotein particles can also
contribute to modulation of the lipoprotein particles [15],
including altered spatial distribution of lipids and therefore also
alternation of the function [41,42].
In conclusion, fish oil supplementation for three and seven
weeks alter the plasma lipidomic profile markedly compared to
intake of high-oleic sunflower oil. The selective elevation of TGs
and phospholipids of high carbon number and double bond
content may represent beneficial effects of fish oil supplementation
in healthy subjects. Future studies are needed in order to elucidate
the health benefits of incorporation of long-chain PUFAs into
selective phospholipids classes and TGs.
Supporting Information
Figure S1 Global Root Mean Square Error plot of Y
(RMSEY). RMSE of Y for the global model is plotted as a
function of the number of components. Detailed explanation for
the plot is given in [26].
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Table S1 Significantly altered lipids (Multivariate anal-
yses, p,0.05) in the fish oil (FO) group compared to the
sunflower oil (HOSO) group after three weeks interven-
tion. The corresponding q-values from univariate analyses are
also given.
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